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Abstract
We report a case of multiple mobile intra-cardiac thrombi
accompanying recurrent pulmonary embolism that has
been successfully treated by fibrinolytic therapy. Control
transesophageal echocardiographic examination showed
that prolonged thrombolytic treatment completely
removed the thrombi.
Surgical removal of emboli has been validated but cannot
be proposed to all patients since it is a high-risk interven-
tion. Fibrinolysis is generally efficient but exposes the
patient to risk of migration of the intra-cavity thrombus,
with occasionally deleterious evolution. Systemic throm-
bolytic therapy is usually recommended if (a) it is not
contraindicated and (b) the thrombi are demonstrated in
more than one cardiac chamber, entailing a higher risk of
surgical intervention. However, the infusion rate and
duration of thrombolytic therapy are important determi-
nants of successful and uncomplicated lysis. Low dose
and long infusion time should be chosen to avoid frag-
mentation of the thrombus and related complications.
Case
A 56-year-old man was admitted to our hospital with
chest pain and severe dyspnea at rest. Expiratory ronchus
and S4 gallop were apparent on physical examination.
The patient's systolic/diastolic blood pressures and heart
rate were 160/100 mmHg and 110 beats/min respectively.
Precordial T wave inversion and sinus tachycardia were
seen on electrocardiography. Transthoracic echocardiog-
raphy (TTE) showed multiple floating thrombi in the
right ventricle (3 × 1 × 1 cm) and right atrium (5.5 × 1 × 1
cm). The patient was diagnosed as recurrent pulmonary
embolism on the basis of his history. Initial treatment
comprised nasal oxygen 6 L/min, heparin 5000 U IV bolus
followed by 1000 U/h infusions, diltiazem 25 mg IV (10
min intervals, three times) and aspirin 300 mg/day. The
arterial blood gas analysis was; PO2: 113 mmHg and
PCO2: 37 mmHg. Clinical complaints were relieved after
4 h of the initial treatment. The patient was consulted by
cardiovascular surgeons for surgical removal of the throm-
bus. However, it was thought that TTE might not screen
adequately for additional cardiac thrombi. Urgent trans-
esophageal echocardiography (TEE) was planned to eval-
uate the other cardiac chambers for intracardiac thrombi
before surgery; at that time the patient's hemodynamic
status and physical examination were normal. The patient
was pre-treated with midozolam 1 mg/IV and metoclo-
promide 20 mg/IV. The TEE probe was tolerated very well
and swelled non-traumatically at the first approach. The
total duration of the procedure was 4 min. The TEE dem-
onstrated cylinder-like, mobile echogenic massed in right
atrium (6.5 × 1 × 1.2 cm), right ventricle (4 × 1 × 1 cm)
and left atrium (3 × 1 × 1 cm) (Figure 1). There were no
signs of systemic arterial embolism. Surgical options were
considered but could not be proposed to the patient since
it was not considered feasible to remove all the cardiac
thrombi that were apparent from the TEE examination.
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Intravenous infusion of low doses of streptokinase
(250,000 U bolus followed by 100,000 U/hour) resulted
in complication-free resolution. The right atrial and ven-
tricular mass disappeared from the control transthoracic
echocardiogram after 60 h. No recurrent pulmonary
embolism was induced by the fibrinolysis. The TEE exam-
ination was repeated after 96 h and showed no cardiac
mass (Figure 2). The response to treatment was based on
the diagnosis of thrombus. The patient's clinical com-
plaints were relieved during the thrombolytic therapy.
Heparin treatment was continued after the fibrinolytic
treatment. The continuation therapy consisted of subcuta-
neous deltaparin injections 120 U/kg twice daily, aspirin
300 mg/day, clopidogrel 75 mg/day and famotidin 40
mg/day. The patient had minor bleeding from vein punc-
ture sites but no major hemorrhage.
Laboratory investigation
Rheumatological and oncological examination and labo-
ratory tests were normal. Thoracic, abdominal and pelvic
spiral contrast computerized tomographies were normal
except accessory spleen. Total blood count, peripheral
blood smear and erythrocyte sedimentation rate were nor-
mal. No factor 5 Leiden mutation (G 1691 A) was
detected. Protein C and protein S levels were depressed
but antithrombin-3 was normal (6%, 16% and 111%;
respectively). Anti-cardiolipin antibody was normal (9
IU/ml). HLA-B5, HLA-B27, anti-nuclear antibody and
rheumatoid factor were negative. Ophthalmological
examination showed no significant finding.
Discussion
Cardiac thrombus may be a complication of primary car-
diac, hematological and rheumatological disease [1]. Car-
diac-sourced thromboembolism can be predicted on the
basis of echocardiographic, clinical, electrocardiographic
and laboratory assessments, such as the presence of
spontaneous echocontrast, large hypokinetic cardiac
chambers, mitral stenosis, history of thromboemboli,
atrial fibrillation and increased coagulation markers. In
our case, no cardiac pathology tending to thromboembo-
lism was found. The most likely cause for thrombus for-
mation was the decreased protein C and S.
Protein C is the central component of a major antithrom-
botic regulatory system with both anticoagulant and
profibrinolytic properties. It inactivates factors Va and
VIIIa. Protein S is as a cofactor for these actions of Protein
C. Protein C and Protein S deficiencies are genetic traits
predisposing to the formation of venous clots. Protein C
deficiency is one of several hereditary abnormalities of
haemostatic proteins that have been described in patients
with propensities to thromboembolic complications.
Major morbidity is often seen in these patients. The diag-
nosis of various aspects of hereditary protein C deficiency
in terms of clinical presentation and genetics (both
homozygous and heterozygous states) is important. In
heterozygotes, plasma levels of protein C are usually 35–
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65% normal, whereas most normal individuals have lev-
els between 70% and 130%. Protein C-deficient patients
usually develop venous thrombotic complications
between the ages of 15 and 40 years with a high incidence
of deep venous thrombosis and pulmonary embolism [2].
In addition to the deep veins of the lower extremities,
thrombosis can also occur in the cerebral, retinal,
mesenteric and renal veins and the inferior vena cava.
Most thrombotic lesions appear to develop spontane-
ously; others are associated with trauma, surgery or preg-
nancy. Acquired Protein C and S deficiencies have been
reported in patients with deep venous thrombosis, pul-
monary embolism, acute disseminated intravascular coag-
ulopathy, post-operative state, severe liver disease,
malignancy, infection, hemolytic-uremic syndrome, adult
respiratory distress syndrome and vitamin K deficiency.
Treatment of symptomatic patients is initial heparin ther-
apy followed by coumarin. After multiple thrombotic
events, lifelong oral anticoagulant therapy is necessary.
Homozygous protein C deficiency, a rare but fatal heredi-
tary condition, manifests itself in the newborn with mas-
sive disseminated intravascular coagulopathy and
purpura fulminans [3].
Symptomatic presentation in right side cardiac thrombus
is fragmentation of the thrombus and subsequent pulmo-
nary embolization [4]. The spontaneous prognosis of pul-
monary embolism associated with mobile intra-cardiac
thrombus is poor, and choice of a therapeutic strategy is
often difficult [5,6]. The literature on treatment and ther-
apeutic management of mobile right heart thrombus with
pulmonary embolism gives no clear consensus. Treatment
should be individualized according to the extent of intra-
cardiac thrombus (number and sizes of clots and their
mobility and morphology), likelihood of pre-existing pul-
monary embolism, the patient's cardiopulmonary reserve,
co-morbid conditions, and local expertise with treatment
modalities [7]. Thrombectomy might have been incom-
plete in view of the TEE findings. The outcome of
untreated mobile thrombus is poor. Surgical removal
should be considered for large thrombi. In the event of
mobile multiple intra-cardiac thrombi, surgery might not
be a good choice for their complete removal. In these con-
ditions, thrombolytic therapy might be preferable [8].
Fibrinolysis is generally efficient but exposes the patient to
the risk of migration of the thrombus. Intravenous fibri-
nolytic treatment for multiple intracardiac mobile
thrombi should be given in low doses and for long times
to avoid subsequent migration of the intra-cardiac
thrombus. Indeed, treatment with high doses of intrave-
nous fibrinolytics for short times may complicate with
degradation of the thrombus and facilitate migration
before lysis is complete. The major advantages of throm-
bolysis are ease of administration and independence of
patient's hemodynamic status [9].
Over the past two decades, new thrombolytic agents with
sufficient pharmacological potency and acceptable clini-
cal safety profiles have been evaluated for treating throm-
botic vascular occlusive syndromes such as pulmonary
embolism and deep vein thrombosis [10]. Therapy with
thrombolytic agents for multiple cardiac floating thrombi
is a non-invasive and effective option.
In this paper, we have reported a case of recurrent pulmo-
nary embolism with mobile multiple intra-cardiac
thrombi, in which the disappearance of the thrombi fol-
lowing successful thrombolytic therapy was documented
by TEE examination.
Conclusion
Protein C and S deficiencies should be investigated in all
patients with cardiac-sourced thromboembolism. Analy-
sis of protein C and S activities are important to avoid
underdiagnosis of this pathology.
Several therapeutic approaches are possible in patients
with cardiac thrombi. Surgical removal of the embolus
has been validated but cannot be proposed to all patients
since it is a high-risk intervention. Fibrinolysis is generally
efficient but exposes the patient to the risk of migration of
the intra-cavity thrombus, with occasionally deleterious
evolution [11,12]. Heparin treatment alone has been pro-
posed as an alternative when the other two techniques are
contraindicated. If there is no contraindication for sys-
temic thrombolytic therapy and thrombi are demon-
strated in multiple cardiac chambers, entailing a higher
risk of surgical intervention, thrombolytic therapy is gen-
erally recommended. However, the duration and infusion
rate are important determinants of successful and uncom-
plicated lysis. Low dose and long time infusion should be
chosen to avoid fragmentation of thrombi and related
complications. Assessment in a randomized study is
required to define the appropriate therapeutic strategy.
TTE may be a limited test for complete screening of car-
diac thrombi but TEE is the gold standard for identifying
thrombi. It may be feasible to use it for complete evalua-
tion of the cardiac mass and to obtain an accurate diagno-
sis [13,14].
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